Company / Net Income
Tarsus Pharmaceuticals, Inc. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$66.4M
FY2025
5-year range
-$135.9M / -$13.8M
FY2021-FY2025
Trend
+42.5%
vs FY2024
Sector context
#89 of 216
Health Care
What the data says
At -$66M, Tarsus Pharmaceuticals, Inc.'s net income ranks #89 of 216 in the Health Care sector. Improved from -$136M to -$66M over the past 2 years.
Based on SEC 10-K filings.
-$66M in FY2025.
Improved from -$136M to -$66M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#89 of 216 in Health CareTop 41% of 216This company -$66.4M Sector average $454.3M
▼
-114.6% below sector average
Key checks
Key Insights
- In FY2025, net income increased 42.5% year-over-year.
- Ranks #89 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2018.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$66.4M | +42.5% |
| FY2024 | -$115.6M | +15.0% |
| FY2023 | -$135.9M | -882.8% |
| FY2022 | -$13.8M | +0.0% |
| FY2021 | -$13.8M | +48.4% |
| FY2020 | -$26.8M | -474.1% |
| FY2019 | -$4.7M | -254.1% |
| FY2018 | -$1.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026